Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Amyris, Janssen Biotech ink research agreement
July 2016
SHARING OPTIONS:

EMERYVILLE, Calif.—Amyris Inc. has struck up a research agreement with a commercial license option with Janssen Biotech Inc., part of Janssen Pharmaceutical Co., to be facilitated by Johnson & Johnson Innovation. Per the terms of the deal, the companies will apply Amyris’ µPharm platform technology to develop a customized library to test against a therapeutic target from Janssen. Specifically, Amyris will leverage its µPharm technology to create a library of natural and natural-like compounds and test their efficacy in vivo for hits against an identified target. This platform offers access to scarce natural compounds and creates new diversity based on natural compound scaffolds.
 
“We are helping to take some of the guess work out of new drug discovery, which helps our partners, like Janssen, to be able to more quickly understand target interaction and ultimately discover new therapies faster,” remarked Joel Cherry, president of research and development at Amyris.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.